@Article{ecn.2012.0305,
AUTHOR = {Guadalupe Lima, Janette Furuzawa-Carballeda, Dolores Ramos-Bello, Juan Jakez-Ocampo, Virginia Pascual-Ramos, Carlos A. Núnez-Alvarez, Julio Granados, Luis Llorente},
TITLE = {Genetic association of CCR5 promoter single nucleotide polymorphism in seronegative and seropositive rheumatoid arthritis},
JOURNAL = {European Cytokine Network},
VOLUME = {23},
YEAR = {2012},
NUMBER = {2},
PAGES = {25--28},
URL = {http://www.techscience.com/ECN/v23n2/65748},
ISSN = {1952-4005},
ABSTRACT = {The aim of this study was to investigate the possible role of the CCR5 59029 A→G promoter point
mutation polymorphism in determining the susceptibility to rheumatoid factor-positive and rheumatoid factornegative
rheumatoid arthritis.This polymorphism was assessed in 85 seropositive and 39 seronegative rheumatoid
arthritis patients and in 126 healthy individuals of the same geographic and ethnic origin. We found an increase
in the genetic frequency of the A allele in the 59029 A→G promoter region of the CCR5 receptor in patients
with rheumatoid arthritis compared with healthy controls (p = 0.01; OR = 1.5, 95% CI (1.0-2.2). Likewise, the
homozygous state for the A allele was found to be more frequent in rheumatoid arthritis patients, again when
compared with healthy controls (p = 0.03; OR = 1.8, 95% CI 1.0-3.0). The increased frequency of the A allele was
more evident in the more benign, seronegative rheumatoid arthritis group when compared with controls (p = 0.003;
OR 2.4 95% CI 1.3-4.4), and when combining the A homozygous and the AG heterozygous patients compared with
healthy subjects. These results suggest that this CCR5 promoter polymorphism seems to play an important role in
determining different clinical courses in both forms of rheumatoid arthritis.},
DOI = {10.1684/ecn.2012.0305}
}